| Literature DB >> 25404941 |
Ashwin Rammohan1, Sathya D Cherukuri1, Jeswanth Sathyanesan1, Ravichandran Palaniappan1, Manoharan Govindan1.
Abstract
Background. Xanthogranulomatous cholecystitis (XGC) is often misdiagnosed as gallbladder cancer (GBC). We aimed to determine the preoperative characteristics that could potentially aid in an accurate diagnosis of XGC masquerading as GBC. Methods. An analysis of patients operated upon with a preoperative diagnosis of GBC between January 2008 and December 2012 was conducted to determine the clinical and radiological features which could assist in a preoperative diagnosis of XGC. Results. Out of 77 patients who underwent radical cholecystectomy, 16 were reported as XGC on final histopathology (Group A), while 60 were GBC (Group B). The incidences of abdominal pain, cholelithiasis, choledocholithiasis, and acute cholecystitis were significantly higher in Group A, while anorexia and weight loss were higher in Group B. On CT, diffuse gallbladder wall thickening, continuous mucosal line enhancement, and submucosal hypoattenuated nodules were significant findings in Group A. CT findings on retrospect revealed at least one of these findings in 68.7% of the cases. Conclusion. Differentiating XGC from GBC is difficult, and a definitive diagnosis still necessitates a histopathological examination. An accurate preoperative diagnosis requires an integrated review of clinical and characteristic radiological features, the presence of which may help avoid radical resection and avoidable morbidity in selected cases.Entities:
Year: 2014 PMID: 25404941 PMCID: PMC4227324 DOI: 10.1155/2014/253645
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Ultrasound showing smooth uniform thickening of gallbladder wall.
Figure 2Contrast-enhanced CT showing smooth circumferential gallbladder wall thickening with a continuous contrast—enhanced mucosal line.
Figure 3Histopathology slide of XGC showing foamy macrophages and giant cells in the wall of the gallbladder.
Comparison of clinical features and tumour markers between XGC and GBC.
| XGC | GBC |
| |
|---|---|---|---|
| Age (mean ± SD) | 56.2 ± 12.4 | 58 ± 11.1 | NS |
| Male/female | 6/9 | 25/35 | NS |
| Abdominal pain (%) | 16 (100) | 37 (61) |
|
| Acute cholecystitis (%) | 12 (75) | 9 (15) |
|
| Cholelithiasis (%) | 11 (68.8) | 17 (28.3) |
|
| Choledocholithiasis (%) | 4 (25) | 2 (3.3) |
|
| Loss of weight (%) | 3 (18.8) | 36 (60) |
|
| Loss of appetite (%) | 9 (56) | 42 (70) |
|
| Diabetes (%) | 5 (31.3) | 18 (30) | NS |
| Jaundice | 2 (12.5) | 8 (13.3) | NS |
| Palpable mass | 5 (18.8) | 7 (11.7) | NS |
| Tumour markers | |||
| CEA (≥4 ng/mL) | 0 | 49 |
|
| CA19.9 (≥20 IU/mL) | 2 | 41 |
|
Comparison of radiological findings between XGC and GBC.
| Radiological findings | XGC | GBC |
|
|---|---|---|---|
| GB wall thickness (mean ± SD, mm) | 14.1 ± 4.9 | 13.6 ± 6.1 | NS |
| Diffuse GB wall thickening | 4 (36.6%) | 4 (6.6%) |
|
| Continuous mucosal line | 8 (50%) | 6 (10%) |
|
| Submucosal hypoattenuated nodules/band | 9 (56.2%) | 10 (16.7%) |
|
| Lymph node enlargement | 10 (62.5%) | 53 (88.3%) | NS |
Figure 4Algorithm for management of gallbladder mass with features of XGC.